...Operator Good afternoon, ladies and gentlemen, and welcome to the Lexicon Pharmaceuticals Inc. full stated results from RELIEF-DPN-1. (Operator Instructions) This call is being recorded on November 14, 2022. I would now like to turn the conference over to Mike Kelly. Please go ahead, sir. Mike Kelly Thank you, Andrew. Good afternoon, and welcome to the Lexicon Pharmaceuticals conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer; and Dr. Anand Patel, Chief Medical Officer at Conquest Research. Earlier today, Lexicon issued a press release reporting full results from the RELIEF-DPN-1 Phase II proof-of-concept study of LX9211 in painful diabetic neuropathy, which was also presented at the 16th Annual Pain Therapeutics Summit by Dr. Patel. Copy of that press release as well as a webcast of this call and the slide presentation...